Anteris Technologies Global (ASX:AVR) ROE %: -66.17% (As of Mar. 2026)


ASX:AVR Anteris Technologies Global Corp ASX:AVR
50 GF Score
Price A$15.00
! 7 Warning Signs
View Full Analysis

What is Anteris Technologies Global ROE %?

Anteris Technologies Global ASX:AVR +10.05% 50 ROE % is -66.17% as of Mar. 2026. GuruFocus rates ASX:AVR with a GF Score™ of 50/100. The stock has 7 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 91.86% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Anteris Technologies Global's annualized net income for the quarter that ended in Mar. 2026 was A$-131.24 Mil. Anteris Technologies Global's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was A$198.32 Mil. Therefore, Anteris Technologies Global's annualized ROE % for the quarter that ended in Mar. 2026 was -66.17%.

The historical rank and industry rank for Anteris Technologies Global's ROE % or its related term are showing as below:

ASX:AVR' s ROE % Range Over the Past 10 Years
Min: -322.16   Med: -185.03   Max: -31.64
Current: -136.26

During the past 13 years, Anteris Technologies Global's highest ROE % was -31.64%. The lowest was -322.16%. And the median was -185.03%.

ASX:AVR's ROE % is ranked worse than
91.86% of 799 companies
in the Medical Devices & Instruments industry
Industry Median: 2.42 vs ASX:AVR: -136.26

Anteris Technologies Global  (ASX:AVR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-131.236/198.322
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-131.236 / 2.816)*(2.816 / 227.2945)*(227.2945 / 198.322)
=Net Margin %*Asset Turnover*Equity Multiplier
=-4660.37 %*0.0124*1.1461
=ROA %*Equity Multiplier
=-57.79 %*1.1461
=-66.17 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-131.236/198.322
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-131.236 / -127.716) * (-127.716 / -136.84) * (-136.84 / 2.816) * (2.816 / 227.2945) * (227.2945 / 198.322)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0276 * 0.9333 * -4859.38 % * 0.0124 * 1.1461
=-66.17 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Anteris Technologies Global ROE % Related Terms


Anteris Technologies Global ROE % Historical Data

* Premium members only.

The historical data trend for Anteris Technologies Global's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anteris Technologies Global ROE % Chart

Anteris Technologies Global Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -273.13 -320.85 -322.98 -187.91 -286.35

Anteris Technologies Global Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -165.47 -241.20 -626.02 -6,432.35 -66.17

ASX:AVR vs INMD, QDEL, SSII: ROE % Comparison

For the Medical Devices subindustry, Anteris Technologies Global's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies Global ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's ROE % distribution charts can be found below:

* The bar in red indicates where Anteris Technologies Global's ROE % falls into.


ASX:AVR
50GF Score
Anteris Technologies Global Corp ASX:AVR
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anteris Technologies Global ROE % Calculation

Anteris Technologies Global's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-141.687/( (99.1+-0.14)/ 2 )
=-141.687/49.48
=-286.35 %

Anteris Technologies Global's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-131.236/( (-0.14+396.784)/ 2 )
=-131.236/198.322
=-66.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -66.17% mean?
Anteris Technologies Global (ASX:AVR) has a ROE % of -66.17% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #734 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 91.9%.
Is Anteris Technologies Global's ROE % too high?
Anteris Technologies Global's current ROE % is -66.17%. Based on the distribution chart, Anteris Technologies Global ranks #734 out of 799 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's ROE % compare to INMD and QDEL?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #734 out of 799 companies for ROE %. This places Anteris Technologies Global in the lower half of its industry. The industry median ROE % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current ROE % is -66.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current ROE % of -66.17%. The current ROE % is -66.17%. Anteris Technologies Global's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current ROE % is -66.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anteris Technologies Global Business Description

Other Exchanges AVR:USA
Address 9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score

Get the complete analysis for ASX:AVR

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$15.00
Price